Neimeth International Pharmaceuticals Plc (NGX:NEIMETH)
Nigeria · Delayed Price · Currency is NGN 8.55
-0.45 (-5.00%)
At close: Jun 11, 2026
NGX:NEIMETH Income Statement
Financials in millions NGN. Fiscal year is January - December.
Millions NGN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 |
| 7,914 | 7,369 | 4,485 | 2,210 | 2,919 | 2,703 | |
Revenue Growth (YoY) | 56.92% | 64.29% | 102.98% | -24.31% | 8.01% | -11.29% |
Cost of Revenue | 4,699 | 4,335 | 2,550 | 1,500 | 1,886 | 1,629 |
Gross Profit | 3,215 | 3,033 | 1,936 | 709.15 | 1,033 | 1,074 |
Selling, General & Admin | 1,768 | 1,800 | 1,286 | 1,636 | 1,204 | 1,125 |
Other Operating Expenses | -873.36 | -935.85 | -1,183 | -1,225 | -157.95 | -26.15 |
Operating Expenses | 894.65 | 863.83 | 103.7 | 410.42 | 1,046 | 1,099 |
Operating Income | 2,320 | 2,169 | 1,832 | 298.73 | -12.39 | -24.8 |
Interest Expense | -1,427 | -1,322 | -873.32 | -667.95 | -300 | -181.77 |
Interest & Investment Income | 215.7 | 249.57 | 231.39 | 129.23 | - | - |
Currency Exchange Gain (Loss) | 214.85 | 214.85 | -2,048 | -1,451 | 1.94 | 96.89 |
EBT Excluding Unusual Items | 1,323 | 1,312 | -858.03 | -1,691 | -310.45 | -109.67 |
Gain (Loss) on Sale of Assets | 1.5 | 1.2 | 3.6 | 0.97 | - | - |
Pretax Income | 1,325 | 1,313 | -854.43 | -1,690 | -310.44 | -109.66 |
Income Tax Expense | 340.37 | 336.5 | 30.9 | 107.88 | 14.6 | - |
Net Income | 984.32 | 976.42 | -885.33 | -1,798 | -325.04 | -109.66 |
Net Income to Common | 984.32 | 976.42 | -885.33 | -1,798 | -325.04 | -109.66 |
Shares Outstanding (Basic) | 4,273 | 4,273 | 4,273 | 4,273 | 1,899 | 1,899 |
Shares Outstanding (Diluted) | 4,273 | 4,273 | 4,273 | 4,273 | 1,899 | 1,899 |
Shares Change (YoY) | - | - | - | 125.00% | - | - |
EPS (Basic) | 0.23 | 0.23 | -0.21 | -0.42 | -0.17 | -0.06 |
EPS (Diluted) | 0.23 | 0.23 | -0.21 | -0.42 | -0.17 | -0.06 |
Free Cash Flow | 1,507 | 1,229 | -306.71 | -1,710 | -1,137 | -1,205 |
Free Cash Flow Per Share | 0.35 | 0.29 | -0.07 | -0.40 | -0.60 | -0.63 |
Gross Margin | 40.62% | 41.16% | 43.16% | 32.09% | 35.39% | 39.74% |
Operating Margin | 29.32% | 29.44% | 40.84% | 13.52% | -0.43% | -0.92% |
Profit Margin | 12.44% | 13.25% | -19.74% | -81.35% | -11.13% | -4.06% |
Free Cash Flow Margin | 19.04% | 16.68% | -6.84% | -77.37% | -38.95% | -44.57% |
EBITDA | 2,501 | 2,334 | 1,962 | 424.82 | 96.02 | 94.78 |
EBITDA Margin | 31.61% | 31.68% | 43.74% | 19.23% | 3.29% | 3.51% |
D&A For EBITDA | 181.37 | 164.91 | 129.99 | 126.09 | 108.41 | 119.57 |
EBIT | 2,320 | 2,169 | 1,832 | 298.73 | -12.39 | -24.8 |
EBIT Margin | 29.32% | 29.44% | 40.84% | 13.52% | -0.42% | -0.92% |
Effective Tax Rate | 25.69% | 25.63% | - | - | - | - |
Advertising Expenses | - | 314.07 | 192.93 | 363.67 | - | 188.49 |